Aviragen Therapeutics (AVIR) Misses Q4 EPS by 5c

Aviragen Therapeutics (NASDAQ: AVIR) reported Q4 EPS of ($0.40), $0.05 worse than the analyst estimate of ($0.35).

For earnings history and earnings-related data on Aviragen Therapeutics (AVIR) click here.

You May Also Be Interested In

• New leader board: Citi refreshes AI compute semiconductor picks
• Atlas Lithium receives expansion permit for Neves lithium project in Brazil
• Streamex's GLDY token available via Siebert brokerage accounts